tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Merus N.V. Shareholders to Vote on Genmab Acquisition Offer
PremiumCompany AnnouncementsMerus N.V. Shareholders to Vote on Genmab Acquisition Offer
3M ago
Cautious Hold Rating on Merus Amid Genmab Acquisition Uncertainty and Promising Pipeline
Premium
Ratings
Cautious Hold Rating on Merus Amid Genmab Acquisition Uncertainty and Promising Pipeline
4M ago
Merus NV’s Financial Stability at Risk Due to Unproven ADClonics Technology and Supply Chain Vulnerabilities
Premium
Company Announcements
Merus NV’s Financial Stability at Risk Due to Unproven ADClonics Technology and Supply Chain Vulnerabilities
4M ago
Cautious Optimism: Hold Rating on Merus Amid Promising Yet Inconclusive Phase II Data for Petosemtamab
PremiumRatingsCautious Optimism: Hold Rating on Merus Amid Promising Yet Inconclusive Phase II Data for Petosemtamab
4M ago
Cautious Hold Rating on Merus: Promising Efficacy in CRC Amidst Limited Data
Premium
Ratings
Cautious Hold Rating on Merus: Promising Efficacy in CRC Amidst Limited Data
4M ago
Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference
Premium
The Fly
Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference
4M ago
Cautious Optimism: Hold Rating on Merus Amid Anticipation of Phase II Data Presentation and Genmab Acquisition
PremiumRatingsCautious Optimism: Hold Rating on Merus Amid Anticipation of Phase II Data Presentation and Genmab Acquisition
4M ago
Genmab price target raised to $49 from $46 at Truist
Premium
The Fly
Genmab price target raised to $49 from $46 at Truist
4M ago
Merus downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Merus downgraded to Market Perform from Outperform at Leerink
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100